ArticleOncotarget2019

CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma.

Adi Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.